Site
Search results (8 results)
-
References | 4 Mar 2014
Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.
-
References | 6 Jun 2013
Limited utility of current MRI criteria for distinguishing multiple sclerosis from common mimickers: primary and secondary CNS vasculitis, lupus and Sjogren's syndrome.
Kim SS, Richman DP, Johnson WO, Hald JK, Agius MAMult Scler. 2013 Jun 4. PMID: 23736535. Abstract -
References | 2 Apr 2014
Fingolimod Therapy in Early Multiple Sclerosis: An Efficacy Analysis of the TRANSFORMS and FREEDOMS Studies by Time Since First Symptom.
Agius M, Meng X, Chin P, Grinspan A, Hashmonay RCNS Neurosci Ther. 2014 Mar 31. PMID: 24684973. Abstract -
References | 13 Mar 2013
Genome wide differences of gene expression associated with HLA-DRB1 genotype in multiple sclerosis: A pilot study.
Apperson ML, Tian Y, Stamova B, Ander BP, Jickling GC, Agius MA, Sharp FRJ Neuroimmunol. 2013 Mar 8. PMID: 23477965. Abstract -
References | 13 Aug 2015
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Hughes B, Cascione M, Freedman MS, Agius M, Kantor D, Gudesblatt M, Goldstick LP, Agashivala N, Schofield L, McCague K, et al.Mult Scler Relat Disord. 2014 Sep; 3(5):620-8. Epub 2014 Jul 03. PMID: 26265274. Abstract -
References | 22 Mar 2016
Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial.
Hunter SF, Agius M, Miller DM, Cutter G, Barbato L, McCague K, Meng X, Agashivala N, Chin P, Hollander EJ Neurol Sci. 2016 Jun 15; 365:190-8. Epub 2016 Mar 22. PMID: 27206905. Abstract -
References | 2 Apr 2014
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA, Radue E-W, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, et al.Lancet Neurol. 2014 Mar 27. PMID: 24685276. Abstract -
References | 10 Aug 2016
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.
Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, et al.Contemp Clin Trials. 2016 Sep; 50:166-77. Epub 2016 Aug 10. PMID: 27521810. Abstract